A four-lab POI SAQ is easy to miss because it tests whether you can identify the phase of the workup. Once premature ovarian insufficiency has been confirmed, listing pregnancy testing, repeat FSH, estradiol, prolactin, or AMH answers whether the diagnosis is correct or what else could mimic amenorrhea. It does not answer why ovarian function was lost.
The second trap is treating thyroid-stimulating hormone and thyroid peroxidase antibodies as interchangeable. They are not, and current guidance has shifted from some older teaching resources.
Start by classifying the case, not by recalling four tests
Assume an illustrative stem describes a 31-year-old with established POI, no known chemotherapy or pelvic radiotherapy, no ovarian surgery, and no prior bilateral oophorectomy. The question asks what should be investigated to identify the cause.
Before choosing tests, confirm the history that makes an etiologic panel appropriate:
- Is the POI spontaneous or clearly iatrogenic?
- Was there chemotherapy, pelvic radiation, ovarian surgery, or bilateral salpingo-oophorectomy?
- Is the presentation primary or secondary amenorrhea?
- Is there a family history of POI, Fragile X–related disease, intellectual disability, or unexplained early menopause?
- Are there symptoms or diagnoses suggesting thyroid or adrenal autoimmunity?
If bilateral ovaries were removed before age 40, the cause is already established and additional etiologic testing is unnecessary. The genetic and adrenal portions of the four-slot framework are mainly for non-iatrogenic or otherwise unexplained POI; TSH remains a separate thyroid-function assessment at diagnosis.
If the prompt says “after confirmation,” do not spend your first line re-proving the diagnosis.
The current four-slot framework
For a non-iatrogenic POI stem, a defensible current answer is built around three etiologic investigations plus thyroid-function assessment:
| Investigation | What it answers | How to phrase its role |
|---|---|---|
| Chromosomal analysis, usually karyotype | Is there a sex-chromosome abnormality, mosaicism, or structural X-chromosome abnormality? | Recommended for non-iatrogenic POI; it can identify Turner-spectrum disease or other chromosomal causes. |
| Specific FMR1 premutation analysis | Is there an FMR1 CGG-repeat expansion associated with POI and familial reproductive risk? | Request a repeat-expansion test, not merely a routine multigene panel. |
| 21-hydroxylase autoantibodies | Is there evidence of adrenal autoimmunity that could signal current or future adrenal insufficiency? | Use in POI of unknown cause; a positive result prompts adrenal-function assessment and endocrine follow-up. |
| Thyroid-stimulating hormone | Is there an associated thyroid disorder requiring evaluation or treatment? | Measure at POI diagnosis; this is thyroid-function assessment, not proof of autoimmune oophoritis. |
The wording matters. A positive 21-hydroxylase antibody result does not by itself diagnose Addison disease or prove that the ovary is being attacked by autoimmunity. It identifies a clinically important adrenal-risk pathway that needs follow-up.
Likewise, a normal karyotype does not eliminate genetic disease. It removes many chromosomal explanations, but FMR1 testing remains a separate molecular test. After appropriate genetic counseling, additional sequencing may be considered where available, especially when initial studies are unrevealing; it is not a substitute for specific FMR1 repeat analysis.
The TPO-versus-TSH trap
Many older teaching resources list thyroid peroxidase antibodies as one of the four investigations. The reasoning is understandable: autoimmune thyroid disease is associated with POI, and TPO antibodies can support thyroid autoimmunity.
However, current international POI guidance recommends measuring TSH at diagnosis and does not recommend routine TPO-antibody screening as part of the autoimmune POI workup. A 2024 Society for Endocrinology guideline lists TPO antibodies among tests that could be considered in a broader possible workup, but it explicitly notes that no firm recommendation can be made from current evidence. Local teaching materials and answer keys may therefore differ.
The board-preparation lesson is not to memorize that one test is always right in every setting. It is to distinguish the categories:
- TSH assesses thyroid function and is part of routine assessment at POI diagnosis.
- TPO antibodies assess thyroid autoimmunity and may be considered selectively or expected by an older source.
- Neither test establishes the diagnosis of POI itself.
- Neither test proves autoimmune ovarian destruction.
If answering a source-bound SAQ whose expected key explicitly names TPO antibodies, you can list them while adding the modern qualification that routine TPO screening is not universally recommended. That shows you understand both the syllabus and the evidence update rather than blindly reproducing a memorized list.
Tests that do not belong in the four etiologic slots
A useful correction exercise is to sort familiar investigations by the question they answer:
| Test or assessment | Main purpose | Why it does not replace the etiologic panel |
|---|---|---|
| Pregnancy test | Exclude pregnancy in amenorrhea | Important early in evaluation, but not a cause of confirmed POI. |
| Repeat FSH or estradiol | Confirm or clarify ovarian insufficiency | Diagnostic confirmation is different from identifying etiology. |
| AMH | May help when the diagnosis is uncertain | It is not a primary diagnostic test and does not identify the cause. |
| Prolactin or 17-hydroxyprogesterone | Evaluate alternative causes of amenorrhea when clinically indicated | These tests belong to differential diagnosis, not a routine post-confirmation POI panel. |
| Anti-ovarian antibodies | Attempt to identify autoimmune ovarian disease | Current guidance does not recommend them as a reliable diagnostic test. |
| DXA, lipid profile, glucose assessment | Assess consequences and comorbidity | Important care after diagnosis, but not etiologic investigations. |
The common reasoning error is category substitution: choosing a familiar test because it is associated with amenorrhea, rather than asking whether it explains the cause of ovarian insufficiency.
A second error is antibody inflation—assuming that every positive antibody has the same diagnostic meaning. In POI, 21-hydroxylase antibodies have a specific clinical consequence because they can identify patients at risk for adrenal insufficiency. TPO antibodies are different: they may support thyroid autoimmunity, but routine positivity does not establish autoimmune POI.
A third error is method mismatch. A standard next-generation sequencing panel may not detect an FMR1 repeat expansion reliably. The test must match the genetic abnormality being sought.
A realistic retrieval exercise for this SAQ
Set aside 12 minutes and work without notes.
Minute 1–3: generate the answer
Write four investigations for a patient with confirmed, non-iatrogenic POI. Do not look at a guideline or question bank. Next to each test, write a five-to-eight-word purpose.
Minute 4–7: force the classification
Sort these into three columns: confirm POI, identify cause, and assess consequences or associated disease. Use pregnancy testing, FSH, AMH, karyotype, FMR1 analysis, 21-hydroxylase antibodies, TSH, TPO antibodies, and DXA.
The aim is not speed. It is to make the category boundary visible.
Minute 8–10: repair the outdated fourth slot
Write two versions of the answer:
- Current international framework: chromosomal analysis, FMR1 premutation testing, 21-hydroxylase antibodies when the cause is unknown, and TSH at diagnosis.
- Older or source-specific framework: use TPO antibodies instead of TSH only when that is clearly the expected teaching answer, and label it as thyroid autoimmunity rather than a mandatory universal test.
Minute 11–12: compress the response
Rewrite the answer as four numbered lines, each containing the test and its purpose. Then repeat the exercise 48 hours later from a blank page. Delayed retrieval is more valuable here than rereading the explanation because the examination task is generation under constraint.
Practical takeaways
- Separate diagnostic confirmation from etiologic investigation before listing tests.
- For non-iatrogenic POI, remember chromosomal analysis, specific FMR1 premutation testing, and 21-hydroxylase antibodies when the cause is unknown.
- Include TSH as thyroid-function assessment at diagnosis; do not automatically treat TPO antibodies as a current universal requirement.
- A positive 21-hydroxylase antibody result prompts adrenal evaluation; it does not independently prove autoimmune oophoritis or Addison disease.
- Do not substitute AMH, repeat FSH, prolactin, anti-ovarian antibodies, or DXA for the etiologic workup.
- Revise this topic by retrieving the test-purpose pairs, then correcting the TSH-versus-TPO distinction from memory.
